Skip to content
  • Report Harm
  • Receive Newsletter
  • Press Room
Facebook Linkedin YouTube Instagram X Spotify
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions, Lawsuits and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Sleeping Pills: What You Need to Know
      • Xanax Study Outcomes
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Detox, Cold Turkey, Abrupt Cessation
      • Dosages Prevent Safe Withdrawal
      • Estimates of Withdrawal
      • The Maudsley Deprescribing Guidelines
      • How To Find Tapering Help
      • Phenobarbital
      • Tapering Strategies and Solutions
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • Benzodiazepines and COVID-19
      • Older Adults
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
  • Our ImpactExpand
    • Media Outreach
    • Press Room
    • Programs
    • Research and Publications
    • Past Speaking and Events
    • Upcoming Events
  • ResourcesExpand
    • Find Support
    • Benzodiazepine Cooperative Providers
    • Information
  • Contact Us
  • Blog
  • Donate
Donate
Facebook Linkedin X Instagram YouTube Spotify
Benzodiazepine Information Coalition

Accessibility statement

Accessibility Statement for https://www.benzoinfo.com

Benzodiazepine Information Coalition is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards.

Conformance status

The Web Content Accessibility Guidelines (WCAG) defines requirements for designers and developers to improve accessibility for people with disabilities. It defines three levels of conformance: Level A, Level AA, and Level AAA.

Benzodiazepine Information Coalition is making constant efforts to improve the accessibility of its site and services in the belief that it is our collective moral obligation to allow seamless, accessible, and unhindered use for those of us with disabilities.

We aim to make all pages and content on https://www.benzoinfo.com accessible, but some content may not yet fully meet the highest accessibility standards. This could be due to challenges in identifying the most suitable technological solution.

We may revise this Statement periodically to reflect improvements or changes to our accessibility practices.

Feedback

We welcome your feedback on the accessibility of Benzodiazepine Information Coalition website. Please let us know if you encounter accessibility barriers on our website:

E-mail: bic@benzoinfo.com

We try to respond to feedback within 3–5 business days.

This statement was created on 2/22/2025.

Newsletter

Get notified about the latest studies, updates, calls to action, media opportunities, and more!

Support BIC

Join us in making a difference today by supporting BIC with a tax-deductible donation.

Donate

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Medical Disclaimer
Online Interaction Policy
Privacy Policy

Facebook Linkedin YouTube Instagram Twitter Spotify

© 2025 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions, Lawsuits and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Sleeping Pills: What You Need to Know
      • Xanax Study Outcomes
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Detox, Cold Turkey, Abrupt Cessation
      • Dosages Prevent Safe Withdrawal
      • Estimates of Withdrawal
      • The Maudsley Deprescribing Guidelines
      • How To Find Tapering Help
      • Phenobarbital
      • Tapering Strategies and Solutions
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • Benzodiazepines and COVID-19
      • Older Adults
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
  • Our Impact
    • Media Outreach
    • Press Room
    • Programs
    • Research and Publications
    • Past Speaking and Events
    • Upcoming Events
  • Resources
    • Find Support
    • Benzodiazepine Cooperative Providers
    • Information
  • Contact Us
  • Blog
  • Donate
Search